ArticleParasites & vectors2025
First quantitative assessment of the effects of parasite control in dogs and cats in the UK.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Infectious Dermatitis in Companion Animals: A One Health Perspective.Animals : an open access journal from MDPI · 2026Article
- Pharmacokinetics, Absolute Bioavailability, and Nonlinear Topical Absorption of a Fluralaner-Moxidectin Spot-On Formulation in Cats.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDogs and cats in the UK are routinely exposed to a range of internal and external parasites that can adversely affect their health and welfare. Among endoparasites, roundworms and lungworms are of particular concern, while ectoparasites such as fleas and ticks remain persistent veterinary challenges. Although preventive parasiticide use is widespread, its broader health and economic benefits have not been comprehensively quantified. Moreover, evolving parasite epidemiology and increasing scrutiny of the environmental impacts of some treatments have prompted debate about their continued use. This study presents a preliminary modelling framework designed to estimate the health and economic benefits of parasite prevention in UK companion animals, focusing on averted infections and associated veterinary cost savings.
methodsA spreadsheet-based model was developed using available data on parasite prevalence, parasiticide usage, treatment frequency, and estimated veterinary costs, supplemented by expert consultation. Two scenarios were assessed: (A) current parasiticide coverage, and (B) optimal coverage assuming full adherence to recommended treatment guidelines.
resultsPreliminary findings suggest that existing parasite control measures targeting Toxocara canis, Toxocara cati, Angiostrongylus vasorum, fleas, and ticks prevent approximately 5.5 million infections in UK dogs and cats each year. Under optimal compliance, the number of averted infections could increase by 70.6%, reaching 9.3 million annually. Economically, current prevention practices are estimated to save UK households around £53 million per year in veterinary costs, with potential savings rising to £95.2 million under optimal coverage and reduced parasite prevalence.
conclusionsThese findings underscore the substantial health and economic value of preventive parasite control in UK pets. While the model relies on simplified assumptions and available data that may overrepresent higher-risk populations, it provides a valuable foundation for future refinement. Incorporating more granular epidemiological, geographical, and seasonal data will enhance precision. As a preliminary framework, this model reinforces the importance of preventive strategies and highlights the potential for even enhanced impact through improved compliance and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.